Effect of Mastiha supplementation on NAFLD: The MAST4HEALTH Randomised, Controlled Trial.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Amerikanou Charalampia, Kanoni Stavroula, Kaliora Andriana C, Barone Angela, Bjelan Mladen, D'Auria Giuseppe, Gioxari Aristea, Gosalbes María José, Mouchti Sofia, Stathopoulou Maria G, Soriano Beatriz, Stojanoski Stefan, Banerjee Rajarshi, Halabalaki Maria, Mikropoulou Eleni V, Kannt Aimo, Lamont John, Llorens Carlos, Marascio Fernando, Marascio Miriam, Roig Francisco J, Smyrnioudis Ilias, Varlamis Iraklis, Visvikis-Siest Sophie, Vukic Milan, Milic Natasa, Medic-Stojanoska Milica, Cesarini Lucia, Campolo Jonica, Gastaldelli Amalia, Deloukas Panos, Trivella Maria Giovanna, Francino M Pilar, Dedoussis George V, MAST4HEALTH consortium
Аннотация
METHODS AND RESULTS: Ninety-eight patients with NAFLD in three countries (Greece, Italy, Serbia) are randomly allocated to either Mastiha or Placebo for 6 months, as part of a multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial. The authors assess NAFLD severity via magnetic resonance imaging (MRI) scanning and LiverMultiScan technique and evaluate the effectiveness of Mastiha through medical, anthropometric, biochemical, metabolomic, and microbiota assessment. Mastiha is not superior to Placebo on changes in iron-corrected T1 (cT1) and Liver Inflammation Fibrosis score (LIF) in entire patient population; however, after BMI stratification (BMI ≤ 35 kg m-2 and BMI > 35 kg m-2 ), severely obese patients show an improvement in cT1 and LIF in Mastiha versus Placebo. Mastiha increases dissimilarity of gut microbiota, as shown by the Bray-Curtis index, downregulates Flavonifractor, a known inflammatory taxon and decreases Lysophosphatidylcholines-(LysoPC) 18:1, Lysophosphatidylethanolamines-(LysoPE) 18:1, and cholic acid compared to Placebo.
CONCLUSION: Mastiha supplementation improves microbiota dysbiosis and lipid metabolite levels in patients with NAFLD, although it reduces parameters of liver inflammation/fibrosis only in severely obese patients.